Trial · NCT02343224
Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
NCT02343224, Phase 2, Completed, Emory University; results first posted 2022-01-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas. Trials, record NCT02343224. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02343224
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
- NCT number
- NCT02343224
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas
- Interventions
- Pegylated interferon alpha-2b
- First posted
- 2015-01-21
- Last updated
- 2022-01-24
- Results first posted
- 2022-01-24
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Children Responding to Treatment | Month 12 | The objective response of study participants was categorized as complete response, partial response, or stable disease. Determination of tumor response or progression is based on the pre-study baseline scan performed closest to time of study entry. The overall response assessment takes into account response in both target and non-target lesion, and the appearance of new lesions. Complete response is defined as the disappearance of all target lesions and non-target lesions, and no new lesions. Partial response is defined as ≥ 65% decrease in the sum of the products of the three perpendicular diameters of all target lesions, and no development of new lesions. Stable disease is defined as neither sufficient decrease in the sum of the products of the three perpendicular diameters of all target lesions to qualify for partial response, nor sufficient increase in a single target lesion to qualify for progressive disease, as well as no new lesions. |
| Secondary | Number of Participants Meeting Event Free Survival Criteria | Month 12, Month 24 | Event free survival is the time to treatment failure from the time of study enrollment to tumor progression, tumor recurrence, death from any cause or occurrence of a second malignant neoplasm. |
| Secondary | Number of Participants Meeting Overall Survival Criteria | Month 12, Month 24 | Overall survival is measured as the time from study enrollment to death from any cause. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Children Responding to Treatment | Month 12 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Meeting Event Free Survival Criteria | Month 12, Month 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Meeting Overall Survival Criteria | Month 12, Month 24 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Children Responding to Treatment | PEGINTRON | Complete Response | 0 | Participants | |
| Number of Children Responding to Treatment | PEGINTRON | Partial Response | 0 | Participants | |
| Number of Children Responding to Treatment | PEGINTRON | Stable Disease | 5 | Participants | |
| Number of Participants Meeting Event Free Survival Criteria | PEGINTRON | Month 12 | 7 | Participants | |
| Number of Participants Meeting Event Free Survival Criteria | PEGINTRON | Month 24 | 7 | Participants | |
| Number of Participants Meeting Overall Survival Criteria | PEGINTRON | Month 12 | 7 | Participants | |
| Number of Participants Meeting Overall Survival Criteria | PEGINTRON | Month 24 | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PEGINTRON | 9 | |
| Overall Study | COMPLETED | PEGINTRON | 0 | |
| Overall Study | NOT COMPLETED | PEGINTRON | 9 |
Source ClinicalTrials.gov
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain, grade 1 | Gastrointestinal disorders | PEGINTRON | 1 | 9 | |
| other | Increased alanine transaminase (ALT), grade 1 | Hepatobiliary disorders | PEGINTRON | 5 | 9 | |
| other | Decreased absolute neutrophil count (ANC), grade 1 | Blood and lymphatic system disorders | PEGINTRON | 1 | 9 | |
| other | Anorexia, grade 2 | General disorders | PEGINTRON | 1 | 9 | |
| other | Increased aspartate aminotransferase (AST), grade 1 | Hepatobiliary disorders | PEGINTRON | 2 | 9 | |
| other | Constipation, grade 2 | Gastrointestinal disorders | PEGINTRON | 1 | 9 | |
| other | Cough, grade 1 | Respiratory, thoracic and mediastinal disorders | PEGINTRON | 1 | 9 | |
| other | Dizziness, grade 1 | General disorders | PEGINTRON | 1 | 9 | |
| other | Dry skin, grade 1 | Skin and subcutaneous tissue disorders | PEGINTRON | 1 | 9 | |
| other | Anemia, grade 1 | Blood and lymphatic system disorders | PEGINTRON | 4 | 9 |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | PEGINTRON | 2 | 9 |
| Total, other adverse events | PEGINTRON | 9 | 9 |
| Total, serious adverse events | PEGINTRON | 1 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02343224
GET https://conductscience.org/api/trials/v1/NCT02343224/events?page=2